An inherited form of blindness directly comparable to a common inherited optic nerve disease in humans has been discovered in ...

Three 2026 Breakthrough Prize winners reflect on developing Luxturna, a gene therapy that treats blindness caused by rare ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

Researchers at the Eye Genetics Research Unit at Children's Medical Research Institute (CMRI) are the first in the world to use stem cells to study one of the genetic causes of Leber Congenital ...

Female sex hormones can significantly enhance the progression of the rare neurodegenerative eye disease retinitis pigmentosa (RP), according to a preclinical study by researchers at UT Southwestern ...

Steven Pittler, Ph.D., at the University of Alabama at Birmingham has sought to find modifier genes for the hereditary eye disorder retinitis pigmentosa type 59. After onset in one’s late teens, RP59 ...

Spread the loveThe recent announcement from a multinational research team regarding a novel CRISPR gene therapy has sparked excitement and hope among millions affected by genetic blindness. In a ...

Diseases that affect the retina, the light-sensitive layer at the back of the eye, are a significant cause of visual impairment and blindness. Gene therapy holds promise for treating some of these ...

MeiraGTx (MGTX) shares added ~18% in the premarket on Monday after the genetic medicines company announced a broad strategic collaboration with Eli Lilly (LLY) to develop and commercialize gene ...

A major international study led by Flinders University has identified a genetic contributor to juvenile glaucoma.